Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $223.2 million.

  • Arrowhead Pharmaceuticals' Operating Expenses rose 3618.53% to $223.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $790.4 million, marking a year-over-year increase of 2577.26%. This contributed to the annual value of $731.1 million for FY2025, which is 2091.71% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Operating Expenses of $223.2 million as of Q4 2025, which was up 3618.53% from $212.4 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Operating Expenses' 5-year high stood at $223.2 million during Q4 2025, with a 5-year trough of $61.0 million in Q1 2021.
  • In the last 5 years, Arrowhead Pharmaceuticals' Operating Expenses had a median value of $121.5 million in 2023 and averaged $133.4 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Operating Expenses soared by 10010.14% in 2021 and then tumbled by 1102.02% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Operating Expenses (Quarter) stood at $90.8 million in 2021, then rose by 15.34% to $104.7 million in 2022, then skyrocketed by 33.83% to $140.1 million in 2023, then increased by 17.0% to $163.9 million in 2024, then surged by 36.19% to $223.2 million in 2025.
  • Its last three reported values are $223.2 million in Q4 2025, $212.4 million for Q3 2025, and $193.3 million during Q2 2025.